Your browser doesn't support javascript.
loading
Safety and tolerability of andecaliximab as monotherapy and in combination with an anti-PD-1 antibody in Japanese patients with gastric or gastroesophageal junction adenocarcinoma: a phase 1b study.
Yoshikawa, Akie Kimura; Yamaguchi, Kensei; Muro, Kei; Takashima, Atsuo; Ichimura, Takashi; Sakai, Daisuke; Kadowaki, Shigenori; Chin, Keisho; Kudo, Toshihiro; Mitani, Seiichiro; Kitano, Shigehisa; Thai, Dung; Zavodovskaya, Marianna; Liu, JieJane; Boku, Narikazu; Satoh, Taroh.
Afiliação
  • Yoshikawa AK; Department of Gastroenterology, Osaka City University Graduate School of Medicine, Osaka, Japan.
  • Yamaguchi K; Department of Gastroenterology, Japanese Foundation for Cancer Research, Tokyo, Japan.
  • Muro K; Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan.
  • Takashima A; Division of Gastrointestinal Medical Oncology, National Cancer Center Hospital, Tokyo, Japan.
  • Ichimura T; Department of Gastrointestinal Oncology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.
  • Sakai D; Department of Frontier Science for Cancer and Chemotherapy, Osaka University Graduate School of Medicine, Osaka, Japan.
  • Kadowaki S; Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan.
  • Chin K; Department of Gastroenterological Chemotherapy, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.
  • Kudo T; Department of Medical Oncology, Osaka International Cancer Institute, Osaka, Japan.
  • Mitani S; Department of Medical Oncology, Kindai University, Higashiosaka, Japan.
  • Kitano S; Department of Experimental Therapeutics, National Cancer Center Hospital, Goyang, Republic of Korea.
  • Thai D; Gilead Sciences Inc, Foster City, California, USA.
  • Zavodovskaya M; Gilead Sciences Inc, Foster City, California, USA.
  • Liu J; Gilead Sciences Inc, Foster City, California, USA.
  • Boku N; Division of Gastrointestinal Medical Oncology, National Cancer Center Hospital, Tokyo, Japan.
  • Satoh T; Department of Frontier Science for Cancer and Chemotherapy, Osaka University Graduate School of Medicine, Osaka, Japan taroh@cfs.med.osaka-u.ac.jp.
J Immunother Cancer ; 10(1)2022 01.
Article em En | MEDLINE | ID: mdl-34992093
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Gástricas / Adenocarcinoma / Junção Esofagogástrica / Anticorpos Monoclonais Humanizados Idioma: En Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Gástricas / Adenocarcinoma / Junção Esofagogástrica / Anticorpos Monoclonais Humanizados Idioma: En Ano de publicação: 2022 Tipo de documento: Article